| Register
| Log out
Submit An Article

ASX:IMU

Latest Articles

  • Issues clinical trial update of its Phase 1 MAST trial

    Issues clinical trial update of its Phase 1 MAST trial

    Clinical stage immuno-oncology company Imugene Limited (ASX:IMU) provided a clinical trial update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA). Patient hits major milestone in CF33 MAST VAXINIA study, with ‘complete response’ for over two years The Cohort review committee has cleared

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.